PMID- 15698400
OWN - NLM
STAT- MEDLINE
DCOM- 20050526
LR  - 20171116
IS  - 1478-3223 (Print)
IS  - 1478-3223 (Linking)
VI  - 25
IP  - 1
DP  - 2005 Feb
TI  - Hepatocellular carcinoma--survival and clinical characteristics in relation to 
      various histologic molecular markers in Western patients.
PG  - 62-9
AB  - BACKGROUND: Many genes participate in the regulation of cell proliferation and 
      growth of tumor cells. Altered expression and loss of function of some of these 
      gene products have been found in malignant tumors and correlated with progression 
      and poor prognosis. AIMS: Our aim was to correlate the expression of various 
      molecular histologic markers with tumor characteristics and survival time of 
      patients with hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Tumor tissues 
      of 81 patients with HCC were investigated immunohistochemically for the 
      expression of cellular proliferation markers Mib1 (Ki67) and c-erbB-2 (HER2/neu), 
      cellcycle markers (p53, mdm2 and p21), CD81 (TAPA1), a marker shown to be 
      associated with metastasis, and human leukocyte antigen (HLA)-DR expression, 
      involved in immunological antigen presentation. RESULTS: p21 was expressed in a 
      higher percentage (83.3 vs. 50%, P=0.014) in undifferentiated histological tumor 
      grades (Edmondson Steiner G3 vs. G1/G2). HCC in patients with enlarged lymph 
      nodes expressed HLA-DR in a higher percentage (28.6%) than tumors without lymph 
      node enlargement (5.7%, P=0.006). Patients with distant metastases were less 
      likely to express CD 81 (11.1%) on tumor cells than patients without distant 
      metastases (38.3%, P=0.0335). No other correlation with clinical or tumor 
      characteristics or molecular histologic markers investigated was found. P53 
      accumulating patients showed a worse survival than patients with tumors p53 
      non-accumulating (median 4.1 months vs. median 9.3 months, P=0.01798). Neither 
      the expression nor the non-expression of proliferation, cell cycle, immunologic 
      or cell adhesion markers was associated with differences in survival. However, 
      patients with a low expression of cell cycle marker mdm2 survived significantly 
      longer (median 9.4 months) as compared with patients with high expression (median 
      3.9 months). CONCLUSION: Our results suggest that p53 nuclear accumulation and 
      mdm2 high expression are associated with poor survival in patients withHCC. 
      Furthermore, patients with enlarged lymph nodes had HLA-DR-positive tumors more 
      frequently and patients with distant metastases had tumors with CD81 expression 
      less often.
FAU - Schoniger-Hekele, Maximilian
AU  - Schoniger-Hekele M
AD  - Universitatsklinik fur Innere Medizin IV, Klinische Abteilung Gastroenterologie 
      und Hepatologie, University of Vienna, A-1090 Vienna, Austria.
FAU - Hanel, Sabine
AU  - Hanel S
FAU - Wrba, Fritz
AU  - Wrba F
FAU - Muller, Christian
AU  - Muller C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Antigens, CD)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD81 protein, human)
RN  - 0 (CDKN1A protein, human)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p21)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Tetraspanin 28)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.3.2.27 (MDM2 protein, human)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
CIN - Liver Int. 2006 Oct;26(8):1018-9. PMID: 16953844
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, CD/metabolism
MH  - Austria/epidemiology
MH  - *Biomarkers, Tumor/metabolism
MH  - Carcinoma, Hepatocellular/metabolism/*mortality/secondary
MH  - Cell Cycle Proteins/metabolism
MH  - Cell Proliferation
MH  - Cyclin-Dependent Kinase Inhibitor p21
MH  - Female
MH  - HLA-DR Antigens/metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - Ki-67 Antigen/metabolism
MH  - Liver Neoplasms/metabolism/*mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Nuclear Proteins/metabolism
MH  - Proto-Oncogene Proteins/metabolism
MH  - Proto-Oncogene Proteins c-mdm2
MH  - Receptor, ErbB-2/metabolism
MH  - Survival Rate
MH  - Tetraspanin 28
MH  - Tumor Suppressor Protein p53/metabolism
EDAT- 2005/02/09 09:00
MHDA- 2005/05/27 09:00
CRDT- 2005/02/09 09:00
PHST- 2005/02/09 09:00 [pubmed]
PHST- 2005/05/27 09:00 [medline]
PHST- 2005/02/09 09:00 [entrez]
AID - LIV997 [pii]
AID - 10.1111/j.1478-3231.2004.0997.x [doi]
PST - ppublish
SO  - Liver Int. 2005 Feb;25(1):62-9. doi: 10.1111/j.1478-3231.2004.0997.x.